CommercialCoverageMedium impact
Policy Criteria Change
Arkansas Blue Cross Blue Shield·AR · Oncology, Hematology·Medical Policy
Effective date
Jul 15, 2026
We identified it
Jun 19, 2026
Summary
Arkansas Blue Cross added restricted coverage for one-time DPYD genetic testing to guide fluoropyrimidine chemotherapy dosing in cancer patients. Repeat testing and other related genetic tests (TYMS, 5-fluorouracil assay testing) are not covered.
Action Required
Before July 15, 2026: Billing team must update systems to ensure DPYD genetic testing is billed only once per patient for fluoropyrimidine dosing guidance in cancer treatment. Verify coverage criteria are met before billing. Stop billing repeat DPYD testing, TYMS genetic testing, and 5-fluorouracil assay testing as these will be denied.